openPR Logo
Press release

Telmisartan Market Analysis by Type, Stage, End-User Appraised By Top Players C.H. Boehringer Sohn AG & Ko. KG, Glenmark Generics Inc

03-15-2019 12:34 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Telmisartan Market

Telmisartan Market

Availability of better treatment options for hypertension has lead substantial portion of the hypertensive population with controlled blood pressure. But rising population with cardiovascular, and associated disorders urges need for different antihypertensive drugs in the global market. Telmisartan is a non-peptide angiotensin receptor blocker intended for treatment of hypertension and other cardiovascular disorders. Telmisartan was approved by the US Food and Drug Administration (USFDA) in 1998, for the treatment of hypertension alone or in combination with other compounds.

Download PDF Brochure Of This Research Report @ www.coherentmarketinsights.com/insight/request-pdf/2524

The global telmisartan market size was valued at US$ 3,880.9 million in 2017, and is expected to witness a CAGR of 1.4% over the forecast period (2018 – 2026).

Increasing number of government initiatives for creating awareness regarding cardiovascular and blood pressure disorders is expected to drive growth of the Telmisartan market

The Texas Council on cardiovascular disease and stroke works with key players to implement plan for reducing rate of cardiovascular disease and stroke burden in Texas. The plan provides an overview of the current state of cardiovascular disease and stroke in Texas, summary of findings from the heart disease and stroke prevention system assessment, as well as information on mortality, morbidity, prevalence, and related risk factors.

Rising prevalence of hypertension globally is creating disease burden and propelling demand for developing antihypertensive drugs in the global market. For instance, the National Health and Nutrition Examination Surveys (NHANES) provided important epidemiologic information on the prevalence and control of hypertension in the U.S., between 1960 and 2014, which stated that 26 percent of the world’s adult population (972 million) was suffering from hypertension in 2000, while number increased by 31 percent (1.39 billion) in 2010, and the number is estimated to reach 1.56 billion by 2025.

Market Dynamics

Prevalence of high blood pressures, is increasing globally attributed to rising geriatric population, chronic disorders such as diabetes, and changing lifestyles which in turn is expected to increase the demand for telmisartan in global market. According to Blood Pressure UK, 2017 update, high blood pressure is the leading cause of heart disease and stroke, killing around 7.5 million people worldwide every year. In 1975, 594 million people were suffering from high blood pressure which increased to 1.1 billion in 2015 and is thought to be due to population growth and an aging population. Thus, rise in geriatric population suffering from high blood pressure is expected to be major factor for growth of telmisartan market in the forecast period.

Furthermore, increasing approvals for Abbreviated new Drug Application (ANDA) for manufacturing of generic telmisartan tablets is propelling growth of telmisartan in the global market. For instance, in July 2014, Glenmark Generics Inc., USA—a subsidiary of Glenmark Generics Limited—received ANDA approval from the U.S. Food and Drug Administration (USFDA) for telmisartan tablets.

Browse Complete Report For More Information @ www.coherentmarketinsights.com/market-insight/telmisartan...

Key players covered as a part of this study include C.H. Boehringer Sohn AG & Ko. KG, Glenmark Generics Inc., Torrent Pharmaceuticals Ltd., Solco Healthcare U.S., Mylan Inc., Aurobindo Pharma Limited, Yichang Changjiang Pharmaceutical Co., Ltd, Wanbang Biopharmaceuticals, and Nippon Boehringer Ingelheim Co., Ltd.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Telmisartan Market Analysis by Type, Stage, End-User Appraised By Top Players C.H. Boehringer Sohn AG & Ko. KG, Glenmark Generics Inc here

News-ID: 1656915 • Views: 151

More Releases from Coherent Market Insights

Training Market World's Top Players Include Skillsoft Limited, Safety Media, GP …
The global training market was valued at US$ 94,828.5 Mn in 2017 and is expected to exhibit a CAGR of 6.4% over the forecast period and reach US$ 174,596.6 Mn in 2027. North America accounted for 45.1% of the revenue share in the global training market in 2018. The Asia Pacific market is witnessing high growth due to increasing demand for cost effective learning management solutions. Moreover, an increase in
5G Infrastructure Market To Witness Double Digit Cagr By 2027
5G is a key enabler for the futuristic digital world. It offers ultra-high broadband infrastructure, for application in various sectors such as healthcare, automotive, and manufacturing. Increasing number of connected devices plays a key role in growth of the 5G infrastructure market. For In depth Information Get Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1343 Software-Defined Networking segment is projected to account for the dominant position in global 5G infrastructure market over
Semiconductor IP Market Top Keyplayers Arm, Synopsys, Cadence, Imagination, Latt …
A semiconductor Intellectual Property (IP) is a logic unit or logic chip that can be reused and is an intellectual property of a circuit. This IP is used in integrated circuit designs or field-programmable gate array (FPGA) logic designs as building blocks. Semiconductor intellectual property enables faster chip design by using existing blocks. It is also responsible for improving the quality of any device, in turn enhancing the efficiency of
Online Marketing Place for Hospitality Services Market Top Keyplayers Hotwire, H …
The desktop platform holds a dominant position in the global online marketing place for hospitality services market, whereas, the mobile platform is expected to grow with the largest CAGR over the forecast period, owing to increasing popularity of mobile apps and mobile-based websites. In addition to this, the increasing number of smart phone users is a major factor providing swift growth to the mobile platform of this market. Online Marketing

All 12046 Releases


More Releases for Telmisartan

Telmisartan Market Keyword Market Breaking down into Type and Key Companies Medt …
Availability of better treatment options for hypertension has lead substantial portion of the hypertensive population with controlled blood pressure. But rising population with cardiovascular, and associated disorders urges need for different antihypertensive drugs in the global market. Telmisartan is a non-peptide angiotensin receptor blocker intended for treatment of hypertension and other cardiovascular disorders. Telmisartan was approved by the US Food and Drug Administration (USFDA) in 1998, for the treatment of
Telmisartan Market Prophesied to Grow at a Faster Pace by 2026
Availability of better treatment options for hypertension has lead substantial portion of the hypertensive population with controlled blood pressure. But rising population with cardiovascular, and associated disorders urges need for different antihypertensive drugs in the global market. Telmisartan is a non-peptide angiotensin receptor blocker intended for treatment of hypertension and other cardiovascular disorders. Telmisartan was approved by the US Food and Drug Administration (USFDA) in 1998, for the treatment of
Telmisartan Sales Market 2017: Rising Demand For Coming Years
Qyresearchreports include new market research report “Global Telmisartan Sales Market Report 2017” to its huge collection of research reports. This report on the global Telmisartan market has been developed by a selected group of professional market research analysts, with a solitary goal to present the current scenario of the market for Telmisartan and throw light on its growth prospects. The report targets audiences such as manufacturers of Telmisartan, government agencies, and
Global Telmisartan Market – Industry Analysis and Future Forecast by 2021 with …
Qyresearchreports include new market research report “Global Telmisartan Market 2016 Industry, Analysis, Research, Share, Growth, Sales, Trends, Supply, Forecast to 2021″ to its huge collection of research reports. The global Telmisartan is the core objective of examination in this research report recently added to our extensive database. The report to a great degree is a spellbinding and savvy archive that helps chalk out a careful and comprehensive investigative Telmisartan, covering
Global Telmisartan Market 2016 Industry, Analysis, Research, Share, Growth, Sale …
The Global Telmisartan Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Telmisartan industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Telmisartan market analysis is provided for the international market including development history, competitive landscape analysis, and major regions development status. Secondly, development policies and plans are discussed as well as manufacturing
Global Telmisartan (144701-48-4) Market 2016 - Teva Pharmaceutical, Divis Labora …
Telmisartan belongs to a class of medications known as angiotensin II receptor antagonists. These medications reduce blood pressure by blocking the actions of a chemical (angiotensin II) that causes blood vessels to constrict or tighten. It is used to treat mild to moderate high blood pressure. Telmisartan is also used to reduce the risk of death after a heart attack in people who cannot use another type of medication called